The virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) causes COVID-19, a potentially fatal disease. The COVID-19 vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2. We reported the case of a 66-year-old woman with a medical history of hypertension and anxious-depressive syndrome who developed Guillain Barré Syndrome (GBS) 4 weeks after receiving the COVID-19 vaccine. During the patient’s hospital stay, they received cycles of high-dose intravenous immunoglobulin (IVIG) and plasmapheresis treatments. Despite the treatment, a deterioration of respiratory function led the patient to premature mortality.
A Death for Guillain-Barrè Syndrome After Receiving a COVID-19 Vaccine: A Case Report / Coviello, A.; Iacovazzo, C.; Vargas, M.; Posillipo, C.; Sagnelli, F.; Diglio, P.; Cirillo, D.; Servillo, G.. - In: CLINICAL MEDICINE INSIGHTS. CASE REPORTS. - ISSN 1179-5476. - 17:(2024). [10.1177/11795476241274692]
A Death for Guillain-Barrè Syndrome After Receiving a COVID-19 Vaccine: A Case Report
Coviello A.;Iacovazzo C.;Vargas M.;Posillipo C.;Sagnelli F.;Diglio P.;Cirillo D.;Servillo G.
2024
Abstract
The virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) causes COVID-19, a potentially fatal disease. The COVID-19 vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2. We reported the case of a 66-year-old woman with a medical history of hypertension and anxious-depressive syndrome who developed Guillain Barré Syndrome (GBS) 4 weeks after receiving the COVID-19 vaccine. During the patient’s hospital stay, they received cycles of high-dose intravenous immunoglobulin (IVIG) and plasmapheresis treatments. Despite the treatment, a deterioration of respiratory function led the patient to premature mortality.File | Dimensione | Formato | |
---|---|---|---|
A Death for Guillain Barrè Syndrome After Receiving a COVID 19 Vaccine A Case Report.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
629.9 kB
Formato
Adobe PDF
|
629.9 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.